Loading company…
StratifAI develops AI-based biomarker tools for precision oncology and breast cancer risk assessment.
Founded in 2023 and based in Dresden, Germany, StratifAI develops Polaris™, a precision oncology platform integrating histology, RNASeq and patient outcomes. Polaris™ Breast assesses metastatic risk in early breast cancer and has been validated on a cohort of over 6,000 patients. The platform is available for research while regulatory approval proceeds in the European Union and United States. In February 2025, the company raised EUR 12.5 million in seed funding led by Picus Capital, with participation from Alven, Heliad Equity Partners, Debiopharm Innovation Fund, Begemann Capital GmbH, MultiplexDX Inc., Neulogy Ventures and ARVE Capital, as well as individual and other unspecified investors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in